Affordable Prescriptions for Patients Through Promoting Competition Act of 2019
Latest action · Oct 2, 2019 Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedSep 19, 2019
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Affordable Prescriptions for Patients Through Promoting Competition Act of 2019
This bill prohibits product hopping by drug manufacturers. Product hopping is presumed when a drug manufacturer engages is a hard switch or a soft switch. A hard switch occurs when, after a manufacturer receives notice of an application for a generic drugs, either, (1) the manufacturer obtains removal of a drug from the Food and Drug Administration’s approved drug list or the drug is moved to the discontinued products list, and the manufacturer markets or sells a follow-on product; or (2) a manufacturer announces the withdrawal or discontinuance of a listed drug, or the manufacturer destroys the inventory of a listed drug in a manner that impedes generic drug competitors, and the manufacturer markets or sells a follow-on product. A follow-on product is a changed, modified, or reformulated version of a manufacturer’s already-approved drug or biological product that still treats the same medical condition.
A soft switch occurs when a manufacturer receives notice of an application for a generic drugs, takes other actions that impede generic drug competitors, and the manufacturer markets or sells a follow-on product.
A drug manufacturer may rebut a presumption of product hopping by demonstrating that its conduct was not intended to limit competition.
Cosponsors
Members who signed on, in the order they did.
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Judiciary Committee | Referred Sep 19, 2019 |
| Administrative State, Regulatory Reform, and Antitrust Subcommittee | Referred Oct 2, 2019 |
Actions 3
Everything that happened, newest first.
- Oct 2, 2019Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
- Sep 19, 2019Introduced in House
- Sep 19, 2019Referred to the House Committee on the Judiciary.
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Constitutional authority
The sponsor’s statement, as printed in the Congressional Record, vol. 165, no. 151, September 19, 2019, page H7836.
CRS reports 2
Congressional Research Service work that CRS links to this bill or the law it became, newest first.
Cite it 2
Products on other subjects that cite it, usually among other measures.
| Product | Title | Kind | Published |
|---|---|---|---|
| R46741 | Drug Pricing and Intellectual Property: The Legislative Landscape for the 117th Congress | Report | Mar 31, 2021 |
| R46221 | Drug Pricing and Pharmaceutical Patenting Practices Archived | Report | Feb 11, 2020 |
Related bills 3
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| S 1416 | Affordable Prescriptions for Patients Act of 2019 | Related bill | Jun 28, 2019 |
| HR 2486 | FUTURE Act | Related bill | Jul 23, 2020 |
| HR 5133 | Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 | Related bill | Dec 24, 2020 |
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To amend the Federal Trade Commission Act to prohibit anticompetitive behaviors by drug product manufacturers, and for other purposes.
- Short Title(s) as Introduced
- Affordable Prescriptions for Patients Through Promoting Competition Act of 2019
Subjects
Assigned by the Library of Congress. Policy area: Commerce.
- Administrative remedies
- Civil actions and liability
- Commerce
- Competition and antitrust
- Consumer affairs
- Drug safety, medical device, and laboratory regulation
- Federal Trade Commission (FTC)
- Health care costs and insurance
- Inflation and prices
- Intellectual property
- Judicial review and appeals
- Manufacturing
- Prescription drugs
Text 1
Each version as it was printed, newest first.
- Sep 19, 2019Introduced in House
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.